Evidence map›Paper›PMID 35808839›Full record

ReviewImmunological reviews2022

Engineered exosomes for studies in tumor immunology.

Ahmet Alptekin, Mahrima Parvin, Hasanul I Chowdhury, Mohammad H Rashid, Ali S Arbab

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Immunological reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ahmet AlptekinGeorgia Cancer Center, Augusta University, Augusta, Georgia, USA.ORCID 0000-0002-7039-1911
Mahrima ParvinGeorgia Cancer Center, Augusta University, Augusta, Georgia, USA.
Hasanul I ChowdhuryGeorgia Cancer Center, Augusta University, Augusta, Georgia, USA.
Mohammad H RashidCedars-Sinai Medical Center, Los Angeles, California, USA.
Ali S ArbabGeorgia Cancer Center, Augusta University, Augusta, Georgia, USA.ORCID 0000-0003-2902-3671
Augusta University Health · USCedars-Sinai Medical Center · US

Funding

Neutrophil Activation after Traumatic Brain InjuryR01NS110378 · NINDS · AUGUSTA UNIVERSITY · PI ARBAB, ALI SYED, BABAN, BABAK · 2019 to 2022
$1.5M
American Heart Association-American Stroke Association 19TPA34850076NINDS NIH HHS R01 NS110378NINDS NIH HHS R01NS110378
6 · The paper itself

Abstract

Exosomes are a type of extracellular vesicle (EV) with diameters of 30-150 nm secreted by most of the cells into the extracellular spaces and can alter the microenvironment through cell-to-cell interactions by fusion with the plasma membrane and subsequent endocytosis and release of the cargo. Because of their biocompatibility, low toxicity and immunogenicity, permeability (even through the blood-brain barrier (BBB)), stability in biological fluids, and ability to accumulate in the lesions with higher specificity, investigators have started making designer's exosomes or engineered exosomes to carry biologically active protein on the surface or inside the exosomes as well as using exosomes to carry drugs, micro RNA, and other products to the site of interest. In this review, we have discussed biogenesis, markers, and contents of various exosomes including exosomes of immune cells. We have also discussed the current methods of making engineered and designer's exosomes as well as the use of engineered exosomes targeting different immune cells in the tumors, stroke, as well as at peripheral blood. Genetic engineering and customizing exosomes create an unlimited opportunity to use in diagnosis and treatment. Very little use has been discovered, and we are far away to reach its limits.

Indexed as

ExosomesExtracellular VesiclesMicroRNAsNeoplasmsCell CommunicationHumansTumor MicroenvironmentMicroRNAsdesigner's exosomesengineered exosomesmanipulation of biogenesis, exosomes, and immune cellsseparation of exosomestherapeutic exosomes

Identifiers

PMID35808839
PMCPMC11044177
OpenAlexW4284990246

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.